Beese Fulmer Investment Management Inc. Boosts Holdings in Novo Nordisk A/S (NYSE:NVO)

Beese Fulmer Investment Management Inc. boosted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 0.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 164,868 shares of the company’s stock after buying an additional 1,260 shares during the quarter. Novo Nordisk A/S accounts for 1.2% of Beese Fulmer Investment Management Inc.’s investment portfolio, making the stock its 28th largest position. Beese Fulmer Investment Management Inc.’s holdings in Novo Nordisk A/S were worth $14,182,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Mather Group LLC. grew its stake in Novo Nordisk A/S by 4.3% during the 3rd quarter. Mather Group LLC. now owns 5,835 shares of the company’s stock worth $695,000 after purchasing an additional 243 shares in the last quarter. Daymark Wealth Partners LLC grew its position in shares of Novo Nordisk A/S by 1.8% during the third quarter. Daymark Wealth Partners LLC now owns 6,402 shares of the company’s stock worth $762,000 after buying an additional 112 shares in the last quarter. Marcum Wealth LLC increased its stake in shares of Novo Nordisk A/S by 2.7% during the third quarter. Marcum Wealth LLC now owns 3,897 shares of the company’s stock worth $464,000 after buying an additional 104 shares during the period. Wedmont Private Capital lifted its stake in Novo Nordisk A/S by 7.8% in the third quarter. Wedmont Private Capital now owns 11,120 shares of the company’s stock worth $1,310,000 after acquiring an additional 809 shares during the last quarter. Finally, Sanibel Captiva Trust Company Inc. grew its holdings in Novo Nordisk A/S by 6.5% during the 3rd quarter. Sanibel Captiva Trust Company Inc. now owns 8,993 shares of the company’s stock worth $1,071,000 after acquiring an additional 547 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on NVO. BMO Capital Markets reduced their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Stock Up 1.7 %

NVO opened at $87.16 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a 12 month low of $78.17 and a 12 month high of $148.15. The stock has a market capitalization of $391.15 billion, a P/E ratio of 28.21, a P/E/G ratio of 0.93 and a beta of 0.45. The business has a 50 day simple moving average of $92.24 and a 200-day simple moving average of $112.01.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 86.32% and a net margin of 35.03%. On average, equities analysts anticipate that Novo Nordisk A/S will post 3.16 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be given a dividend of $0.7874 per share. This represents a dividend yield of 1.2%. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 23.30%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.